TY - JOUR
T1 - Acute and 1-Year Hospitalization Costs for Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention
T2 - Results From the TRANSLATE-ACS Registry
AU - the TRANSLATE-ACS Investigators
AU - Cowper, Patricia A.
AU - Knight, J. David
AU - Davidson-Ray, Linda
AU - Peterson, Eric D.
AU - Wang, Tracy Y.
AU - Mark, Daniel B.
N1 - Funding Information:
Dr Cowper has received grant funding from AstraZeneca, Eli Lilly & Company, GE Healthcare, Bristol Myers Squibb, Pfizer, Tenax Therapeutics, Gilead, Merck, and Novartis (all significant). Dr Peterson has received research grants from Eli Lilly & Company and AstraZeneca and consulting support from AstraZeneca (all significant). Dr Wang has received research grants to the Duke Clinical Research Institute from Amgen (modest), AstraZeneca (significant), Bristol Myers Squibb (modest), Cryolife (significant), Novartis (significant), Pfizer (modest), Portola (significant), and Regeneron (significant), as well as consulting honoraria from Grifols (modest) and Gilead (modest). Dr Mark has received grant funding from Eli Lilly & Company, Merck & Company, Oxygen Therapeutics, and HeartFlow (all significant) and consulting fees from CeleCor, Cytokinetics, and Novo Nordisk (all modest). The remaining authors have no disclosures to report.
Funding Information:
We are particularly indebted to the coordinators at the TRANSLATE-ACS sites who enrolled the study patients and collected the study data and to the patients who agreed to participate in this study.
Funding Information:
This work was supported by grants from Daiichi Sankyo and Lilly USA.
Publisher Copyright:
© 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
PY - 2019/4/16
Y1 - 2019/4/16
N2 - Background: Hospitalization for acute myocardial infarction (MI) in the United States is both common and expensive, but those features alone provide little insight into cost-saving opportunities. Methods and Results: To understand the cost drivers during hospitalization for acute MI and in the following year, we prospectively studied 11 969 patients with acute MI undergoing percutaneous coronary intervention at 233 US hospitals (2010–2013) from the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) registry. Baseline costs were collected in a random subset (n=4619 patients, 54% ST-segment–elevation MI [STEMI]), while follow-up costs out to 1 year were collected for all patients. The mean index length of stay was 3.1 days (for both STEMI and non-STEMI) and mean intensive care unit length of stay was 1.2 days (1.4 days for STEMI and 1.0 days for non-STEMI). Index hospital costs averaged $18 931 ($19 327 for STEMI, $18 465 for non-STEMI), with 45% catheterization laboratory–related and 20% attributable to postprocedure hospital stay. Patient factors, including severity of illness and extent of coronary disease, and hospital characteristics, including for profit status and geographic region, identified significant variations in cost. Intensive care was used for 53% of non-STEMI and increased costs by $3282. Postdischarge 1-year costs averaged $8037, and 48% of patients were rehospitalized (half within 2 months and 57% with a cardiovascular diagnosis). Conclusions: While much of the cost of patients with acute MI treated with percutaneous coronary intervention is probably not modifiable by the care team, cost reductions are still possible through quality-preserving practice efficiencies, such as need-based use rather than routine use of intensive care unit for patients with stable non-STEMI. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00097591.
AB - Background: Hospitalization for acute myocardial infarction (MI) in the United States is both common and expensive, but those features alone provide little insight into cost-saving opportunities. Methods and Results: To understand the cost drivers during hospitalization for acute MI and in the following year, we prospectively studied 11 969 patients with acute MI undergoing percutaneous coronary intervention at 233 US hospitals (2010–2013) from the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) registry. Baseline costs were collected in a random subset (n=4619 patients, 54% ST-segment–elevation MI [STEMI]), while follow-up costs out to 1 year were collected for all patients. The mean index length of stay was 3.1 days (for both STEMI and non-STEMI) and mean intensive care unit length of stay was 1.2 days (1.4 days for STEMI and 1.0 days for non-STEMI). Index hospital costs averaged $18 931 ($19 327 for STEMI, $18 465 for non-STEMI), with 45% catheterization laboratory–related and 20% attributable to postprocedure hospital stay. Patient factors, including severity of illness and extent of coronary disease, and hospital characteristics, including for profit status and geographic region, identified significant variations in cost. Intensive care was used for 53% of non-STEMI and increased costs by $3282. Postdischarge 1-year costs averaged $8037, and 48% of patients were rehospitalized (half within 2 months and 57% with a cardiovascular diagnosis). Conclusions: While much of the cost of patients with acute MI treated with percutaneous coronary intervention is probably not modifiable by the care team, cost reductions are still possible through quality-preserving practice efficiencies, such as need-based use rather than routine use of intensive care unit for patients with stable non-STEMI. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00097591.
KW - acute myocardial infarction
KW - cost
KW - percutaneous coronary intervention
UR - http://www.scopus.com/inward/record.url?scp=85064846346&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064846346&partnerID=8YFLogxK
U2 - 10.1161/JAHA.118.011322
DO - 10.1161/JAHA.118.011322
M3 - Article
C2 - 30975005
AN - SCOPUS:85064846346
SN - 2047-9980
VL - 8
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 8
M1 - e011322
ER -